RxDoctor Payments Data

Abdul Hasnie, MD

Cardiovascular Disease · Flint, MINPI 1619964699

Payments from drug & device makers

$9,303in general payments, 2019–2025

Across 398 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Novartis$2K
  • Medtronic$1K
  • Johnson & Johnson$554
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$474
  • E.r. Squibb & Sons, L.L.C.$450
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$1,73919%
  • Food & beverage$7,25478%
  • Education$3113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,303 in reported general payments places this provider in the 65th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$353,271
Medicare patients
471
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban430$490,636
BrilintaTicagrelor233$198,011
EntrestoSacubitril/Valsartan83$119,955
JardianceEmpagliflozin95$106,648
XareltoRivaroxaban74$82,508
MultaqDronedarone Hcl14$16,041
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine24$11,793
ClopidogrelClopidogrel Bisulfate600$11,374
Atorvastatin Calcium602$9,214
Repatha SureclickEvolocumab11$8,881
Isosorbide Mononitrate ErIsosorbide Mononitrate351$6,567
Nebivolol Hcl77$6,318
Metoprolol Tartrate692$6,129
Metoprolol Succinate294$5,831
Lisinopril577$5,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$245$490,636430 claims
AstraZenecaBrilinta$220$198,011233 claims
NovartisEntresto$1,513$119,95583 claims
Boehringer IngelheimJardiance$164$106,64895 claims
Johnson & JohnsonXarelto$554$82,50874 claims
Sanofi-aventis U.S. LLCMultaq$180$16,04114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →